vs
Side-by-side financial comparison of BEYOND MEAT, INC. (BYND) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.
BEYOND MEAT, INC. is the larger business by last-quarter revenue ($61.6M vs $57.6M, roughly 1.1× Phathom Pharmaceuticals, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs -19.7%). BEYOND MEAT, INC. produced more free cash flow last quarter ($-49.8M vs $-167.0M).
Beyond Meat, Inc., branded as Beyond, is a producer of plant-based meat alternatives founded in 2009 by Ethan Brown. The company's products were first launched in the United States in 2012.
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
BYND vs PHAT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $61.6M | $57.6M |
| Net Profit | — | — |
| Gross Margin | -11.5% | 86.7% |
| Operating Margin | -211.4% | — |
| Net Margin | — | — |
| Revenue YoY | -19.7% | 94.1% |
| Net Profit YoY | — | 71.6% |
| EPS (diluted) | $0.68 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $61.6M | $57.6M | ||
| Q3 25 | $70.2M | $49.5M | ||
| Q2 25 | $75.0M | $39.5M | ||
| Q1 25 | $68.7M | $28.5M | ||
| Q4 24 | $76.7M | $29.7M | ||
| Q3 24 | $81.0M | $16.4M | ||
| Q2 24 | $93.2M | $7.3M | ||
| Q1 24 | $75.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | $-110.7M | $-30.0M | ||
| Q2 25 | $-29.2M | $-75.8M | ||
| Q1 25 | $-52.9M | $-94.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-26.6M | $-85.6M | ||
| Q2 24 | $-34.5M | $-91.4M | ||
| Q1 24 | $-54.4M | — |
| Q4 25 | -11.5% | 86.7% | ||
| Q3 25 | 10.3% | 87.5% | ||
| Q2 25 | 11.5% | 87.2% | ||
| Q1 25 | -1.5% | 86.9% | ||
| Q4 24 | 13.1% | 87.1% | ||
| Q3 24 | 17.7% | 85.6% | ||
| Q2 24 | 14.7% | 81.2% | ||
| Q1 24 | 4.9% | — |
| Q4 25 | -211.4% | — | ||
| Q3 25 | -160.0% | -30.8% | ||
| Q2 25 | -46.6% | -151.7% | ||
| Q1 25 | -81.8% | -276.5% | ||
| Q4 24 | -49.3% | — | ||
| Q3 24 | -38.2% | -433.0% | ||
| Q2 24 | -36.4% | -1055.4% | ||
| Q1 24 | -70.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | -157.6% | -60.5% | ||
| Q2 25 | -39.0% | -191.9% | ||
| Q1 25 | -77.0% | -330.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -32.8% | -523.3% | ||
| Q2 24 | -37.0% | -1248.6% | ||
| Q1 24 | -71.9% | — |
| Q4 25 | $0.68 | — | ||
| Q3 25 | $-1.44 | $-0.41 | ||
| Q2 25 | $-0.38 | $-1.05 | ||
| Q1 25 | $-0.69 | $-1.31 | ||
| Q4 24 | $-0.65 | — | ||
| Q3 24 | $-0.41 | $-1.32 | ||
| Q2 24 | $-0.53 | $-1.56 | ||
| Q1 24 | $-0.84 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $203.9M | $130.0M |
| Total DebtLower is stronger | $415.7M | $209.1M |
| Stockholders' EquityBook value | $-997.0K | $-438.2M |
| Total Assets | $614.7M | $259.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $203.9M | $130.0M | ||
| Q3 25 | $117.3M | $135.2M | ||
| Q2 25 | $103.5M | $149.6M | ||
| Q1 25 | $102.1M | $212.3M | ||
| Q4 24 | $131.9M | $297.3M | ||
| Q3 24 | $121.7M | $334.7M | ||
| Q2 24 | $144.9M | $276.2M | ||
| Q1 24 | $157.9M | — |
| Q4 25 | $415.7M | $209.1M | ||
| Q3 25 | $1.2B | $207.1M | ||
| Q2 25 | $1.2B | $205.1M | ||
| Q1 25 | $1.1B | $203.2M | ||
| Q4 24 | $1.1B | $201.4M | ||
| Q3 24 | $1.1B | $175.7M | ||
| Q2 24 | $1.1B | $174.4M | ||
| Q1 24 | $1.1B | — |
| Q4 25 | $-997.0K | $-438.2M | ||
| Q3 25 | $-784.1M | $-422.5M | ||
| Q2 25 | $-677.0M | $-405.8M | ||
| Q1 25 | $-649.5M | $-338.4M | ||
| Q4 24 | $-601.2M | $-253.6M | ||
| Q3 24 | $-611.9M | $-187.1M | ||
| Q2 24 | $-590.0M | $-233.8M | ||
| Q1 24 | $-561.4M | — |
| Q4 25 | $614.7M | $259.1M | ||
| Q3 25 | $599.7M | $240.3M | ||
| Q2 25 | $691.7M | $250.2M | ||
| Q1 25 | $643.8M | $294.2M | ||
| Q4 24 | $678.1M | $378.3M | ||
| Q3 24 | $692.9M | $387.0M | ||
| Q2 24 | $711.2M | $319.4M | ||
| Q1 24 | $735.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-46.8M | $-166.8M |
| Free Cash FlowOCF − Capex | $-49.8M | $-167.0M |
| FCF MarginFCF / Revenue | -80.8% | -290.0% |
| Capex IntensityCapex / Revenue | 4.8% | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-157.2M | $-328.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-46.8M | $-166.8M | ||
| Q3 25 | $-38.8M | $-14.1M | ||
| Q2 25 | $-33.2M | $-62.7M | ||
| Q1 25 | $-26.1M | $-84.9M | ||
| Q4 24 | $-29.0M | $-266.8M | ||
| Q3 24 | $-22.0M | $-63.6M | ||
| Q2 24 | $-16.0M | $-70.7M | ||
| Q1 24 | $-31.8M | — |
| Q4 25 | $-49.8M | $-167.0M | ||
| Q3 25 | $-41.7M | $-14.1M | ||
| Q2 25 | $-35.1M | $-62.8M | ||
| Q1 25 | $-30.6M | $-84.9M | ||
| Q4 24 | $-35.4M | $-266.9M | ||
| Q3 24 | $-24.1M | $-63.6M | ||
| Q2 24 | $-17.3M | $-70.8M | ||
| Q1 24 | $-33.0M | — |
| Q4 25 | -80.8% | -290.0% | ||
| Q3 25 | -59.4% | -28.6% | ||
| Q2 25 | -46.9% | -159.0% | ||
| Q1 25 | -44.6% | -297.9% | ||
| Q4 24 | -46.2% | -899.8% | ||
| Q3 24 | -29.7% | -389.0% | ||
| Q2 24 | -18.6% | -966.2% | ||
| Q1 24 | -43.7% | — |
| Q4 25 | 4.8% | 0.4% | ||
| Q3 25 | 4.1% | 0.1% | ||
| Q2 25 | 2.6% | 0.2% | ||
| Q1 25 | 6.5% | 0.1% | ||
| Q4 24 | 8.4% | 0.5% | ||
| Q3 24 | 2.5% | 0.3% | ||
| Q2 24 | 1.4% | 0.6% | ||
| Q1 24 | 1.6% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
